Pacer Advisors’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $123K | Sell |
1,083
-1,436
| -57% | -$163K | ﹤0.01% | 2199 |
|
|
2025
Q1 | $265K | Buy |
+2,519
| New | +$265K | ﹤0.01% | 1658 |
|
|
2024
Q1 | – | Sell |
-325,727
| Closed | -$23.3M | – | 3702 |
|
|
2023
Q4 | $23.3M | Buy |
325,727
+121,049
| +59% | +$8.65M | 0.07% | 276 |
|
|
2023
Q3 | $12.3M | Buy |
204,678
+67,928
| +50% | +$4.07M | 0.05% | 295 |
|
|
2023
Q2 | $9.86M | Sell |
136,750
-16,793
| -11% | -$1.21M | 0.04% | 381 |
|
|
2023
Q1 | $11.3M | Buy |
153,543
+41,438
| +37% | +$3.05M | 0.05% | 361 |
|
|
2022
Q4 | $7.49M | Buy |
+112,105
| New | +$7.49M | 0.04% | 373 |
|
|
2022
Q3 | – | Sell |
-93,259
| Closed | -$5.19M | – | 2176 |
|
|
2022
Q2 | $5.19M | Buy |
+93,259
| New | +$5.19M | 0.04% | 362 |
|
|
2021
Q3 | – | Sell |
-2,812
| Closed | -$230K | – | 1428 |
|
|
2021
Q2 | $230K | Sell |
2,812
-796
| -22% | -$65.1K | ﹤0.01% | 1282 |
|
|
2021
Q1 | $343K | Sell |
3,608
-1,525
| -30% | -$145K | 0.01% | 1190 |
|
|
2020
Q4 | $318K | Sell |
5,133
-2,544
| -33% | -$158K | 0.01% | 1142 |
|
|
2020
Q3 | $456K | Buy |
+7,677
| New | +$456K | 0.01% | 1014 |
|
|
2020
Q1 | – | Sell |
-9,565
| Closed | -$622K | – | 911 |
|
|
2019
Q4 | $622K | Sell |
9,565
-2,653
| -22% | -$173K | 0.03% | 721 |
|
|
2019
Q3 | $759K | Sell |
12,218
-941
| -7% | -$58.5K | 0.02% | 900 |
|
|
2019
Q2 | $937K | Buy |
+13,159
| New | +$937K | 0.02% | 827 |
|
|
2018
Q4 | – | Sell |
-2,148
| Closed | -$368K | – | 822 |
|
|
2018
Q3 | $368K | Buy |
+2,148
| New | +$368K | 0.01% | 917 |
|
|
2018
Q1 | – | Sell |
-802
| Closed | -$68K | – | 1089 |
|
|
2017
Q4 | $68K | Buy |
+802
| New | +$68K | ﹤0.01% | 989 |
|